The I-SPY 2 Trial is different from conventional trials due to its adaptive nature and its focus on biomarker-driven treatment. Unlike traditional trials that usually test one drug at a time, I-SPY 2 tests multiple drugs concurrently. This approach not only speeds up the process but also increases the likelihood of finding effective treatments tailored to individual patients.
